Telix Prices US$600M Convertible Bond Offer and Retires 85% of Existing Debt
Telix secures US$600 million in convertible bonds after strong investor demand
Radiopharmaceutical developer Telix Pharmaceuticals (ASX: TLX) has priced and upsized its convertible bond offering from US$550 million to US$600 million due to strong global institutional demand. The 1.50% convertible notes, maturing in April 2031, will be issued by wholly-owned subsidiary Telix Pharmaceuticals (Investments) Inc. and guaranteed by Telix Pharmaceuticals Limited and Telix Pharmaceuticals (US) Inc. Settlement is expected on 22 April 2026.
The upsizing signals robust investor confidence in Telix’s growth trajectory and capital management strategy at a time when the company is expanding its radiopharmaceutical commercialisation pipeline across oncology and rare disease indications.
When big ASX news breaks, our subscribers know first
What are convertible bonds and why do companies issue them?
Convertible bonds are hybrid financial instruments that combine features of both debt and equity. Holders receive regular interest payments like traditional bonds but can convert their holdings into company shares if the share price rises above a predetermined conversion price. This structure benefits companies by offering lower interest rates than conventional debt whilst providing investors with downside protection through guaranteed coupon payments and upside participation if share prices appreciate.
For Telix, the 37.5% conversion premium means investors would only convert to shares if Telix’s stock price rises significantly above current levels. This provides capital-efficient funding that avoids immediate shareholder dilution whilst securing financial flexibility for the company’s development programmes.
Key terms of the new convertible bonds
The Convertible Bonds carry an initial conversion price of US$13.85 (~A$19.55) per Ordinary Share, representing a 37.5% premium over the reference share price of A$14.22 per share. This reference price reflects an 8.0% discount to Telix’s closing price of A$15.45 on 14 April 2026 and a 3.2% discount to the 5-day volume weighted average price of A$14.69.
Interest will be paid quarterly in arrear on 22 January, 22 April, 22 July, and 22 October each year, commencing 22 July 2026. The bonds include an investor put option at the end of year 3, providing flexibility for bondholders to exit early if desired. The Convertible Bonds will be listed on the Singapore Exchange (SGX-ST).
| Term | Detail |
|---|---|
| Issue Size | US$600 million |
| Coupon Rate | 1.50% p.a. (paid quarterly) |
| Maturity | 22 April 2031 (5 years) |
| Conversion Price | US$13.85 (~A$19.55) per share |
| Conversion Premium | 37.5% above A$14.22 reference price |
| Investor Put Option | Available at end of year 3 |
| Listing | SGX-ST |
The bonds rank as direct, unconditional, unsubordinated, and unsecured obligations of the Issuer and Guarantors, with standard anti-dilutive adjustments including conversion price adjustments for all dividends paid by Telix.
Concurrent repurchase retires more than 85% of existing convertible bonds
Telix is simultaneously repurchasing approximately A$637 million of its existing A$650 million convertible bonds due 2029 through a reverse bookbuilding process. The Concurrent Repurchase will result in the cancellation of more than 85% of the Existing Convertible Bonds, with Telix intending to redeem the remaining bonds under its existing rights.
This comprehensive refinancing extends the company’s debt maturity profile from 2029 to 2031 whilst simplifying the capital structure. The transaction demonstrates proactive balance sheet management, allowing Telix to lock in favourable financing terms with a 1.50% coupon rate whilst pushing out debt maturity by two years.
Settlement of both the Offering and the Concurrent Repurchase is expected on 22 April 2026, subject to satisfaction of customary conditions. The repurchased Existing Convertible Bonds will be cancelled in accordance with their terms and conditions.
Stock lending arrangement supports the transaction
Elk River Holdings Pty Ltd as the trustee for The Behrenbruch Family Trust has entered into a stock lending agreement with a J.P. Morgan affiliate over 15 million Ordinary Shares to support the transaction. The stock borrow facility has a term of 11 months and facilitates delta hedging activities by the bookrunner.
Management perspective on the refinancing
Dr Christian Behrenbruch, Managing Director and Group CEO
“The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.”
The statement underscores management’s focus on maintaining financial flexibility to support Telix’s radiopharmaceutical development and commercialisation programmes without resorting to immediate equity dilution.
The next major ASX story will hit our subscribers first
What this means for Telix shareholders
The refinancing transaction delivers several strategic benefits for Telix shareholders:
-
Simplified capital structure through consolidation of 85%+ of existing convertible bonds and issuance of a single new instrument with longer maturity.
-
Extended debt maturity from 2029 to 2031, providing breathing room for commercialisation timelines and reducing near-term refinancing risk.
-
Reduced interest costs with the 1.50% coupon rate on the new bonds potentially lowering overall cost of capital compared to alternative financing options.
-
Protection from near-term dilution through the 37.5% conversion premium, meaning shares would need to appreciate materially from the A$14.22 reference price before conversion becomes likely.
-
Strong institutional validation demonstrated by the upsizing from US$550 million to US$600 million, reflecting robust demand from both existing and new global investors.
The transaction provides Telix with financial flexibility to pursue its radiopharmaceutical pipeline development and commercialisation strategy whilst maintaining a strengthened balance sheet. The company’s ability to access capital on favourable terms positions it to advance multiple programmes across oncology and rare disease therapeutic areas without immediate equity dilution concerns.
J.P. Morgan Securities plc acted as Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.
Get Healthcare News Before the Market Reacts
Join 20,000+ investors receiving FREE breaking ASX healthcare alerts delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start getting market-moving announcements the moment they break, analysed and ready to act on.